Shock Exchange Blog | Talkmarkets | Page 1
Contributor's Links: New York Shock Exchange

B.A. in economics and MBA from top 10 business school. I have over 10 years of M&A / corporate finance experience. Currently head the New York Shock Exchange, a youth mentorship program that teaches investment management skills and ... more

Articles

Latest Posts
1 to 16 of 147 Posts
1 2 3 ... 10
Facebook Cuts Third-Party Data Providers From Ad Targeting
FB is expected to cut third-party data providers from ad targeting. Such data providers may be forced to sell data to advertisers separate from FB. More companies chase the same ad dollars could hurt FB revenue.
Will Rihanna Tete-A-Tete Crush Snap?
Snap and Rihanna had tete-a-tete over an ad making light of domestic violence. Racy ads likely connotes Snap's desperate need to amplify user engagement to grow revenue.
Did Cambridge Analytica Debacle Kill Facebook's Business Model?
The Cambridge Analytica debacle has caused FB shares to fall by double digits. The dust-up could hurt consumer or advertiser sentiment.
Micron Is Sitting In The Catbird Seat
MU reports quarterly earnings after-hours. Top line revenue growth has been gaudy. The company is poised to exploit out-sized growth in memory for eSports and cloud computing.
5 Doctors Charged For Fentanyl Kickbacks; Is Insys At Risk?
Five doctors were charged for writing fentanyl prescriptions in exchange for kickbacks. One doctor was sentenced to four years in prison after admitting he took kickbacks from INSY. Is INSY at risk?
Oracle: It's All About The Cloud
ORCL reports quarterly earnings after-hours. Analysts expect revenue of $9.78 billion and eps of $0.72. The revenue estimate implies about 2% growth sequentially.
Urban Outfitters Is Running In Quicksand
URBN's revenue is rising, operating expenses are outpacing revenue gains. As more sales come from via the digital channel it could stymie margins. Digital is growing but comparable store sales are in decline.
Insys: Will The Drug Pipeline Drive Growth?
INSY's Q4 revenue declined over 40% Y/Y, but was up 3% sequentially. Revenue declines appear to have subsided. Its $163MM of cash and investments could support the company until its drug pipeline kicks in.
Urban Outfitters: All About Guidance
URBN has been on a tear. The company had delivered strong revenue growth without sacrificing much in margins. Whether management can give strong guidance will determine if URBN falls hard or not.
Mallinckrodt: Acthar, Deteriorating Credit Metrics Are Concerning
MNK produced a Q4 revenue beat, yet revenue still fell 5% Y/Y. Acthar revenue was off 9% Y/Y. This is a cause for concern. Debt/EBITDA rose to 4.8x. It could deteriorate further after the Sucampo deal.
Can Valeant Bulls Stomach Double-Digit Revenue Declines?
Can VRX bulls stomach double-digit revenue declines? Asset sales have helped pare debt and reduce corporate overhead. Asset sales could be halted for the moment. If LOE exceeds revenue from new products then VRX's credit metrics could deteriorate.
3 Key Takeaways From The Fed Minutes
The Fed minutes from January affirmed a gradual approach to rate hikes. The Fed wants a sustained return to 2% inflation. If the Fed remains data dependent it might not hike rates at all this year. This could be good for stocks short-term.
Allergan: Europe Halts Esmya Prescriptions Amid Liver Risk Probe
The European Medicines Agency advised that no new patients take Esmya due to potential links to liver injury. The decision could stymie AGN's attempt to seek FDA approval for Esmya in the U.S.
Wage Growth Stokes Inflation Fears
In January the U.S. economy added 200,000 jobs, exceeding the 180,000 experts were expecting. Wage growth of 2.9% was the fastest since 2009. It sent financial markets lower on inflationary expectations.
Valeant: Generic Syprine Is Here
Teva announced the launch of generic Syprine, which treats Wilson's disease. Valeant's Syprine and Cuprimine have combined quarterly revenue and of $38MM. Hits to Syprine and Cuprimine could hurt sentiment for Valeant.
Patent Losses Could Sink Allergan
Allergan reports Q4 earnings on Tuesday. The company faces patent losses for Restasis, Combigan and Estrace. They represent a combined 15% of total revenue.
1 to 16 of 147 Posts
1 2 3 ... 10